创新药
Search documents
节后A股投资主线有哪些?十大券商来了!
Ge Long Hui· 2026-02-24 00:10
春节假期结束,今日A股将正常开市。 回顾节前A股表现,沪指(2月13日)跌1.26%失守4100点,深证成指跌1.28%,创业板指跌1.57%。 本周,特朗普将发表国情咨文,同时将"全球关税"加码至15%于2月24日生效;德国总理默茨或于24日 至26日访华。 AI巨头英伟达及百度发布重磅财报;苹果年度股东大会与iOS 26.4测试版发布在即。此外,伊朗局势、 美联储官员讲话、中国LPR及香港财政预算案等事件也值得关注。 后市市场将如何演绎?且看最新十大券商策略汇总。 中信建投证券研报认为,春节期间全球股市整体强势,无重大风险事件,当前市场情绪仍然高涨,节后 A股有望开启新一轮上行。行业配置上继续坚持"科技+资源品"双主线。其中科技主线以AI、人形机器 人、新能源和创新药为核心,资源品主线以贵金属、石油石化、基础化工为核心。重点关注板块包括: 1.广发策略:A股将迎来"春季躁动"胜率最高的阶段 历史看,2月份及春节前后是春季躁动日历效应最强阶段。市场高胜率、小盘风格占优。以小盘指数为 例,在春节到两会之间上涨概率为100%,在2月上涨概率为87.5%。 在配置方向上,"春季躁动"上涨方向并非是"炒小炒差"、与 ...
节后“红包行情”会否继续?券商分析师假期“连轴转”,关注这些方向
Mei Ri Jing Ji Xin Wen· 2026-02-23 11:43
炒股就看金麒麟分析师研报,权威,专业,及时,全面,助您挖掘潜力主题机会! 每经记者|王海慜 每经编辑|赵云 2026年马年春节假期,虽然A股休市,但资本市场却热度不减。 各大券商分析师们开启"加班模式",以高频路演、专题研报填补假期信息真空。从兴业证券策略团队的 连续七天新春专题路演,到中信证券聚焦AI(人工智能)大模型的系列电话会,再到多家机构跟踪春 节消费动态,头部与中小券商均紧抓假期窗口输出市场观点。 港股马年开市两天呈现结构性行情,2月20日开市首日AI大模型、机器人板块逆势大涨,创新药、氢能 概念股表现亮眼。2月23日,港股大涨。截至收盘,恒生指数涨2.53%,恒生科技指数涨3.34%。 此外,业内预计,美国最高法院关税裁定利好非美市场资产,叠加A股春节效应的历史正向表现,市场 对马年春节后"红包行情"的延续抱有较高期待。 机器人、创新药大热 这场名为"新春专题系列"的直播,内容涵盖港股情绪研究框架、2026年十大产业趋势、全球估值比较、 全球产业映射、出海深度报告等多个维度。张启尧及其团队试图在春节假期这一A股市场"空窗期",通 过高频的观点输出,抢占投资者的注意力高地。 这并非行业个例。多家机构 ...
医药周报:春节期间医药行业重点事件梳理
Guolian Minsheng Securities· 2026-02-23 07:45
Investment Rating - The report maintains a "Recommended" rating for the pharmaceutical industry [5] Core Insights - The underlying logic of the current pharmaceutical industry era is innovation and international expansion, with a focus on innovative drugs and technology-driven sectors [2][3] - The report highlights the strong performance of the CRO market and suggests a dual investment strategy focusing on both "0 to 1" technology innovation and low-position stocks [2][3] - The report emphasizes the ongoing trend of BD (Business Development) transactions in innovative drugs, with significant growth expected in 2026 [4][15] Summary by Sections 1. Key Events in the Pharmaceutical Industry During the Spring Festival - Innovative drug BD transactions have seen a strong start, with significant overseas development and registration progress for key products [13][14] - The total amount of BD transactions for innovative drugs in China for 2026 has already surpassed one-third of the total for 2025 [15] - The revision of the National Essential Medicines List Management Measures may signal changes in the essential medicines directory [28] 2. Pharmaceutical Market Review and Hotspot Tracking - The pharmaceutical sector's performance was relatively weak, with a weekly decline of 0.81%, ranking 20th among all industries [34][38] - The total trading volume for pharmaceuticals was 401.12 billion yuan, accounting for 3.83% of the total market, below the historical average of 7.09% [55] - The report notes a rising valuation level for the pharmaceutical industry, with a PE ratio of 29.25, which is below the historical average [52] 3. Stock Performance Review - The report lists the top-performing stocks, including Dongyangguang and Zhendemedical, while highlighting the underperformers like Huayuan Biology and *ST Sailong [58][59]
国金证券:国内制药供应链景气度上行持续 建议把握CXO行业两大核心主线
Xin Lang Cai Jing· 2026-02-22 11:47
2025年以来,医药行业政策持续优化,集采边际影响减弱并转向质量导向。第十一批集采新增反内卷措 施,通过设置锚点价、复活机制等保障中选率与合理价差,同时提高质量与市场规模门槛。生物类似药 集采有望2026年启动,预计降幅温和。此外,多部门推出全链条支持政策,优化创新药审评审批、招采 准入与支付环节,医保基金向创新药倾斜,商保目录扩容补位,形成多元支付体系,为创新药快速放量 与产业高质量发展保驾护航。 成果已显:创新药企逐步进入收获期 国金证券发布研报称,2025年全球医药投融资触底复苏,前11个月总额达1921亿美元,海内外市场同步 改善,且呈现传统赛道稳健流入、ADC、双抗等新兴赛道加码的特征。2025年以来,AI制药技术热度 攀升、全球创新药景气度延续,再叠加国内生物医药投融资触底回升,行业市场关注度持续走高,基本 面复苏趋势愈发明确。展望2026年,建议把握优先布局行业龙头及聚焦海外业务占比高的标的两大 CXO行业核心主线。 国金证券主要观点如下: 研发能力突破,全球竞争力凸显 2025年全球医药投融资触底复苏,前11个月总额达1921亿美元,海内外市场同步改善,且呈现传统赛道 稳健流入、ADC、双抗等 ...
四环医药(00460) - 自愿公告- 轩竹生物获纳入恒生综合指数成份股
2026-02-22 10:09
香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責,對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明,並 明 確 表 示,概 不 就 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 Sihuan Pharmaceutical Holdings Group Ltd. 四環醫藥控股集團有限公司 四 環 醫 藥 控 股 集 團 有 限 公 司(「本公司」或「四環醫藥」,連 同 其 附 屬 公 司,統 稱 為「本集團」)董 事 會(「董事會」)欣 然 宣 佈,根 據 恒 生 指 數 有 限 公 司 於2026年2月 13日公佈的截至2025年12月31日 止 期 間 之 恒 生 指 數 系 列 季 度 檢 討 結 果,本 集 團 旗 下 非 全 資 附 屬 公 司 軒 竹 生 物 科 技 股 份 有 限 公 司(「軒竹生物」,於 二 零 二 五 年 十 月 十 五 日 在 香 港 聯 合 交 易 所 有 限 公 司(「香港聯交所」)主 板 上 市,股 份 代 號: 2575)被 納 入 恒 生 綜 合 指 數 之 成 分 股,該 調 ...
港股开盘 | 恒指低开0.18% 科网股走低 阿里巴巴(09988)跌超3%
智通财经网· 2026-02-20 01:35
港股马年首个交易日开盘,恒生指数低开0.18%,恒生科技指数跌0.69%。盘面上,油气板块强势,中 国海洋石油涨超2%;科网股集体走弱,阿里巴巴跌超3%。 关于港股后市 著名分析师张忆东在加盟国泰海通后,带领团队发布最新市场研判。首先,政策导向转为积极性和主动 性呵护中国股市。近期随着市场降温,上证4100点以下已经感受到托底的力量。其次,阶段性否极泰 来。港股整体卖空成交占比约19%,其中恒生科技指数卖空成交占比快速回升至21%。海外市场已出现 阶段性跌深反弹迹象,有利于港股短期反弹。 第三,保险为主的配置型战略投资者,开始趁市场调整而加大增持中国股市。第四,中国股市春季行情 的季节性规律,仍有望起作用。历史经验看,春节前市场若偏弱,节后随着资金回流与风险偏好修复, 市场往往更容易走强。中国基本面和资金面,才是决定中国股市行情的核心变量。后续各地两会、全国 两会、十五五规划实施、美国总统访华等一系列政治经济和产业层面的催化频出,内外资共振的增量资 金将推动今年春季行情。投资策略上可持股过节,享受春节红包,把握住近期市场调整倒车接客的时 机,布局2-3月的春季行情。 国联民生证券指出,港股科技前期表现显著滞涨 ...
千亿巨头,大举加仓!
Zhong Guo Ji Jin Bao· 2026-02-19 12:11
Core Insights - Hillhouse Capital's HHLR Advisors revealed its Q4 2025 holdings, showing a significant portfolio adjustment with a total market value of $3.104 billion, a 24% decrease from the previous quarter [2][3]. Group 1: Portfolio Adjustments - HHLR Advisors increased its positions in Alibaba and Pinduoduo, marking them as core holdings, while also initiating a position in the iShares Bitcoin ETF [2][3][8]. - The top ten holdings include seven Chinese concept stocks, which account for 92% of the portfolio, focusing on internet e-commerce, biomedicine, and fintech sectors [3][6]. Group 2: Major Holdings - Pinduoduo remains the largest holding, with shares increasing from 8.59 million to 10.72 million, raising its market value from $1.136 billion to $1.216 billion, now representing 39% of the portfolio [5][6]. - Alibaba, the second-largest holding, saw its shares rise from 3.289 million to 5.43 million, increasing its market value from $588 million to $796 million, now comprising 26% of the portfolio [5][6]. Group 3: Reductions and Exits - HHLR Advisors significantly reduced its holdings in Futu and Webull, with Futu's shares nearly halved from 3.238 million to 1.63 million, and Webull's shares almost fully liquidated [9][10]. - The firm completely exited positions in Baidu, NetEase, and several other non-core stocks [9][10].
兴业证券:2026年值得关注的十大产业趋势
智通财经网· 2026-02-18 03:45
Group 1: AI Applications - The global AI competition is intensifying, with model iterations driving deeper application scenarios, and the focus is on whether significant capital expenditures by tech giants can lead to commercial applications [2][3] - The competitive landscape for AI applications is shifting from dominance by OpenAI to a more multipolar environment, with major players like Google and Meta integrating AI into their ecosystems [3] - In China, AI applications are experiencing a breakthrough, with major tech companies accelerating model iterations and application deployments, leading to a transformation from model landing to scenario monetization [5] Group 2: AI Computing Power - Overseas, major cloud service providers are maintaining high capital expenditures, with a projected increase of 67% in 2026, reflecting a strong demand for AI computing power [7][8] - In China, leading tech companies are increasing capital expenditures and accelerating the iteration of domestic large models, promoting the performance of domestic chips amid tightening supply from foreign sources [9] Group 3: Storage - The demand for storage is entering a new super cycle driven by AI training and inference needs, with AI servers consuming significantly more memory than traditional servers [11][16] - Supply constraints are expected to persist, leading to continued high prices for storage components, as major manufacturers shift production focus to advanced memory types [16] Group 4: Commercial Aerospace - Commercial aerospace is becoming a key battleground in US-China competition, with significant policy support and funding initiatives in both countries to accelerate industry development [19][21] - Domestic companies are achieving breakthroughs in satellite mass production and reusable rocket technologies, transitioning from technical validation to commercialization [22] Group 5: Humanoid Robots - Major overseas companies are ramping up production plans for humanoid robots, benefiting domestic component suppliers, with Tesla aiming for a production capacity of 500,000 units by 2026 [27][30] - Chinese manufacturers are leading in humanoid robot shipments, with significant contracts and production milestones achieved in 2025 [30] Group 6: Intelligent Driving - Domestic policies are expected to facilitate the commercialization of L3 autonomous driving in 2026, with several manufacturers preparing to launch L3 models [32][33] - Tesla's Full Self-Driving (FSD) technology is setting the direction for autonomous driving, with significant advancements in AI capabilities [35] Group 7: Energy Storage - The expansion of AI computing power in North America is driving electricity demand, with domestic power equipment expected to accelerate exports [37][40] - China's "14th Five-Year Plan" includes significant investments in the power grid and energy storage, creating a favorable environment for industry growth [40][43] Group 8: Chemicals - The chemical industry is undergoing a transformation driven by policies aimed at supply-side reform, with a focus on optimizing supply structures and reducing excess capacity [44][47] - New economic sectors are boosting demand for chemical materials, particularly in AI, renewable energy, and robotics, leading to a favorable outlook for new materials [47][48]
汇丰晋信基金总经理李选进:在高质量发展的道路上策“马”扬鞭
Zhong Guo Ji Jin Bao· 2026-02-17 04:25
非常感谢大家对于汇丰晋信基金的支持! 刚刚过去的农历蛇年无疑是充满"惊喜"的一年。从"横空出世"的国产人工智能,到蛇年春晚舞台上惊艳 世界的机器人表演,从国产创新药在国际舞台上备受瞩目,到阅兵方阵上展示的堪称"科幻"的先进装 备,过去几年中国坚定不移贯彻的高质量发展战略,如今已经结出了累累硕果。 反映到资本市场上,在AI、创新药、新消费等"新经济"板块的引领下,2025年的A股和港股市场也都交 出了一份较为满意的"答卷"。上证综指全年涨幅接近20%,恒生指数涨幅接近30%,而集中了较多新经 济企业的科创板综指和创业板指数更是上涨了超过40%和50%,成为全球表现最好的市场之一。 对于公募基金行业来说,2025年同样是向高质量发展迈进的一年。 2025年5月,证监会印发了《推动公募基金高质量发展行动方案》,从费率机制、考核制度、产品结构 等多维度调整优化行业运行逻辑,为公募基金行业未来持续高质量发展指明了方向。在这一精神引领 下,汇丰晋信基金始终秉持初心,坚持"做正确的事",不断升级投研和服务能力,以长期视角服务好投 资者。 李选进 汇丰晋信基金管理有限公司总经理 2003年加盟汇丰投资管理(香港)有限公司,任 ...
港股三大指数蛇年收涨 机构:马年港股或震荡上行
Zhong Guo Zheng Quan Bao· 2026-02-16 05:51
Market Performance - The Hong Kong stock market closed positively on the last trading day of the Year of the Snake, with all three major indices rising: Hang Seng Index up 0.52%, Hang Seng China Enterprises Index up 0.42%, and Hang Seng Tech Index up 0.13% [1][2] - The Hang Seng Composite Industry Index saw all 12 sectors increase, with the materials, energy, and industrial sectors leading the gains at 3.96%, 2.21%, and 0.94% respectively [2][3] Yearly Performance - For the Year of the Snake (January 29, 2025, to February 16, 2026), the Hang Seng Index increased by 32.04%, the Hang Seng China Enterprises Index by 22.87%, and the Hang Seng Tech Index by 13.63% [4] - The top three performing stocks during this period were Junyu Foundation, Base Champion Group, and Jingxi International, with respective gains of 7,836.51%, 3,725.00%, and 2,736.36% [5] Sector Performance - All 31 first-level industries in the Shenwan classification rose, with 24 industries gaining over 30%, 10 industries over 50%, and 2 industries over 100%. The top three performing sectors were non-ferrous metals (189.59%), defense and military (103.90%), and machinery equipment (74.18%) [6] - The artificial intelligence, non-ferrous metals, and innovative pharmaceuticals sectors led the market, with significant price increases for major companies: Huahong Semiconductor up 337.20%, China Life up 143.70%, SMIC up 83.95%, Alibaba up 78.14%, HSBC up 77.30%, and Tencent up 34.01% [6][7] Market Outlook - Analysts expect the Hong Kong market to continue its upward trend in 2026, driven by factors such as ongoing interest rate cuts by the Federal Reserve, deepening domestic policies, improving corporate earnings, and sustained capital inflows [7] - Recommendations for post-Spring Festival market strategies include focusing on consumption, precious metals, energy, and technology sectors, with a barbell allocation strategy suggested for the second half of the year [7]